Table 3.
Therapy for patients with lysozyme-associated nephropathy among those with follow-up (N = 30)
| Categories | N | Therapy |
|---|---|---|
| Alive | 22 | |
| Chronic myelomonocytic leukemia | 10 | 3 azacitidine 3 decitabine, including 1 with venetoclax, and 1 with hydroxyurea and ruxolitinib 1 ruxolitinib 1 hydroxyurea and corticosteroid 2 no treatment |
| Acute myeloid leukemia | 3 | 1 decitabine and venetoclax 1 no therapy 1 unknown |
| Myelodysplastic syndrome | 2 | 1 azacitidine 1 hydroxyurea |
| Neuroendocrine carcinoma | 2 | 2 chemotherapy and radiation therapy, including 1 with lanreotide |
| Essential thrombocythemia | 1 | Ruxolitinib |
| Leprosy | 1 | Azithromycin, dapsone, minocycline |
| Sarcoidosis | 1 | Corticosteroid |
| Unknown | 2 | 1 no therapy 1 unknown |
| Deceased | 8 | |
| Chronic myelomonocytic leukemia | 3 | 1 decitabine and cedazuridine 1 venetoclax 1 chemotherapy NOS |
| Acute myeloid leukemia | 2 | 1 decitabine 1 no chemotherapy |
| Neuroendocrine carcinoma | 1 | Chemotherapy NOS |
| Myelodysplastic syndrome | 1 | No chemotherapy |
| Myelofibrosis | 1 | Ruxolitinib, then palliative care |
NOS, not otherwise specified.